Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Arterial disease is the leading cause of morbidity/mortality in Metabolic syndrome (MetS).
This occurs early as evidenced by arterial dysfunction that, in turn, raises blood pressure
and glucose. Health organizations recommend exercise in an intensity based manner to promote
cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication
that reduces future type 2 diabetes and cardiovascular risk. However, the optimal exercise
dose to be combined with metformin for additive effects on vascular function is unknown.
Based on the investigator's preliminary work, the overall hypothesis is that metformin blunts
adaptation following high intensity exercise training (HiEx) by lowering mitochondrial
derived oxidative stress signaling. The investigators further hypothesize that low intensity
exercise (LoEx) training combined with metformin will promote additive effects on vascular
function compared to LoEx or HiEx+metformin, and maintain/improve non-exercise physical
activity patterns. In this double-blind trial, obese 30-60y MetS participants will be
randomized to: 1) LoEx+placebo; 2) LoEx+metformin, 3) HiEx+placebo; or 4) HiEx+metformin for
16 weeks.